Regarding the anti-inflammatory activity of andrographolide in prostate cancer cells, it has been demonstrated that IL-6 levels are frequently elevated in the serum of many men with advanced, hormone-refractory prostate cancer [63]. Here, IL6 is linked to prostate carcinoma.